The Biden administration is expected to issue new tariffs on Chinese-made medical devices like syringes and personal protective equipment when it unveils its new trade strategy next week, according to two sources familiar with the decision.
Bluebird bio released its first-quarter 2024 business report on Thursday, touting a nearly 140% year-over-year increase in revenue amid the growing uptake of its three gene therapies.
MacroGenics’ stock dropped by as much as 70% Friday morning after the biotech disclosed five deaths in the Phase II TAMARACK trial for its investigational antibody-drug conjugate vobramitamab duocarmazine in metastatic castration-resistant prostate cancer.
Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its COVID-19 vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business.
The 2024 American Society of Gene & Cell Therapy annual meeting attracted a record number of attendees and abstracts, testimony to the tremendous growth of the cell and gene therapy industry. But for me, my week onsite in Baltimore laid bare the major challenges that stand between cell and gene therapies (CGTs) and the masses.
The U.S. drug regulator has pushed back its decision on Moderna’s (MRNA.O) respiratory syncytial virus (RSV) vaccine due to “administrative constraints” and will complete the review by the end of this month, the company said on Friday.